"Catalytic Domain" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The region of an enzyme that interacts with its substrate to cause the enzymatic reaction.
| Descriptor ID |
D020134
|
| MeSH Number(s) |
G02.111.570.120.704 G02.111.570.820.709.275.750.188
|
| Concept/Terms |
Catalytic Domain- Catalytic Domain
- Catalytic Domains
- Domain, Catalytic
- Domains, Catalytic
- Catalytic Subunit
- Catalytic Subunits
- Subunit, Catalytic
- Subunits, Catalytic
- Catalytic Region
- Catalytic Regions
- Region, Catalytic
- Regions, Catalytic
- Catalytic Core
- Catalytic Cores
- Core, Catalytic
- Cores, Catalytic
Active Site- Active Site
- Active Sites
- Site, Active
- Sites, Active
- Catalytic Site
- Catalytic Sites
- Site, Catalytic
- Sites, Catalytic
- Reactive Site
- Reactive Sites
- Site, Reactive
- Sites, Reactive
|
Below are MeSH descriptors whose meaning is more general than "Catalytic Domain".
Below are MeSH descriptors whose meaning is more specific than "Catalytic Domain".
This graph shows the total number of publications written about "Catalytic Domain" by people in this website by year, and whether "Catalytic Domain" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 5 | 5 |
| 2010 | 0 | 6 | 6 |
| 2011 | 0 | 5 | 5 |
| 2012 | 2 | 7 | 9 |
| 2013 | 0 | 11 | 11 |
| 2014 | 0 | 6 | 6 |
| 2015 | 2 | 8 | 10 |
| 2016 | 0 | 4 | 4 |
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 4 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 4 | 4 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Catalytic Domain" by people in Profiles.
-
Mealka M, Sierra NA, Avellaneda Matteo D, Albekioni E, Khoury R, Mai T, Conley BM, Coleman NJ, Sabo KA, Komives EA, Bobkov AA, Cooksy AL, Silletti S, Schiffer JM, Huxford T, Sohl CD. Active site remodeling in tumor-relevant IDH1 mutants drives distinct kinetic features and potential resistance mechanisms. Nat Commun. 2024 May 06; 15(1):3785.
-
Toro TB, Skripnikova EV, Bornes KE, Zhang K, Watt TJ. Endogenous expression of inactive lysine deacetylases reveals deacetylation-dependent cellular mechanisms. PLoS One. 2023; 18(9):e0291779.
-
Piserchio A, Isiorho EA, Dalby KN, Ghose R. Structure of the complex between calmodulin and a functional construct of eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor. J Biol Chem. 2023 06; 299(6):104813.
-
Transue WJ, Snyder RA, Caranto JD, Kurtz DM, Solomon EI. Particle Swarm Fitting of Spin Hamiltonians: Magnetic Circular Dichroism of Reduced and NO-Bound Flavodiiron Protein. Inorg Chem. 2022 Oct 24; 61(42):16520-16527.
-
Al-Horani RA, Parsaeian E, Mohammad M, Mottamal M. Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies. Chem Biol Drug Des. 2022 07; 100(1):64-79.
-
Stokes ES, Gilchrist ML, Calhoun DH. Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the a-galactosidase A active site, dimer interface, and glycosylation region. Protein Expr Purif. 2020 11; 175:105710.
-
Wang Y, Davis I, Chan Y, Naik SG, Griffith WP, Liu A. Characterization of the nonheme iron center of cysteamine dioxygenase and its interaction with substrates. J Biol Chem. 2020 08 14; 295(33):11789-11802.
-
Zarmouh NO, Messeha SS, Mateeva N, Gangapuram M, Flowers K, Eyunni SVK, Zhang W, Redda KK, Soliman KFA. The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells. Molecules. 2020 May 11; 25(9).
-
Selvam C, Mock CD, Mathew OP, Ranganna K, Thilagavathi R. Discovery of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors by Ligand-based Virtual High Throughput Screening. Mol Inform. 2020 07; 39(7):e1900150.
-
Sammons RM, Ghose R, Tsai KY, Dalby KN. Targeting ERK beyond the boundaries of the kinase active site in melanoma. Mol Carcinog. 2019 09; 58(9):1551-1570.